Cargando…

Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients

This study evaluated differences in the clinical appearance of patients with hepatocellular carcinoma (HCC) based on plasma level and regulation of microRNAs (miRNA-29c, miRNA-21, and miRNA-155). The observational-analytical study with a cross-sectional design was conducted on 36 HCC patients and 36...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratnasari, Neneng, Lestari, Puji, Renovaldi, Dede, Raditya Ningsih, Juwita, Qoriansas, Nanda, Wardana, Tirta, Hakim, Suharno, Signa Aini Gumilas, Nur, Indrarti, Fahmi, Triwikatmani, Catharina, Bayupurnama, Putut, Setyo Heriyanto, Didik, Astuti, Indwiani, Mubarika Harjana, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843218/
https://www.ncbi.nlm.nih.gov/pubmed/35157721
http://dx.doi.org/10.1371/journal.pone.0263298
_version_ 1784651208694169600
author Ratnasari, Neneng
Lestari, Puji
Renovaldi, Dede
Raditya Ningsih, Juwita
Qoriansas, Nanda
Wardana, Tirta
Hakim, Suharno
Signa Aini Gumilas, Nur
Indrarti, Fahmi
Triwikatmani, Catharina
Bayupurnama, Putut
Setyo Heriyanto, Didik
Astuti, Indwiani
Mubarika Harjana, Sofia
author_facet Ratnasari, Neneng
Lestari, Puji
Renovaldi, Dede
Raditya Ningsih, Juwita
Qoriansas, Nanda
Wardana, Tirta
Hakim, Suharno
Signa Aini Gumilas, Nur
Indrarti, Fahmi
Triwikatmani, Catharina
Bayupurnama, Putut
Setyo Heriyanto, Didik
Astuti, Indwiani
Mubarika Harjana, Sofia
author_sort Ratnasari, Neneng
collection PubMed
description This study evaluated differences in the clinical appearance of patients with hepatocellular carcinoma (HCC) based on plasma level and regulation of microRNAs (miRNA-29c, miRNA-21, and miRNA-155). The observational-analytical study with a cross-sectional design was conducted on 36 HCC patients and 36 healthy controls. The blood samples were collected from 2 Province Hospitals (Dr. Sardjito Hospital and Prof. Dr. Margono Soekarjo Hospital) for HCC and the Blood Bank Donor of the Indonesian Red Cross for 36 healthy controls. These blood samples were treated as follows: plasma isolation, RNA isolation, cDNA synthesis, quantification by qRT-PCR using a sequence-specific forward primer, and normalization of miRNA using housekeeping-stably miRNA-16. There were only 27 HCC patients with complete clinical variables (neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), platelet count, albumin, C-reactive protein (CRP), and cholinesterase (ChE)) that were able to analyses for regulation miRNAs based on its fold change expression miRNA target. All 27 HCC subjects were follow-up until 3-years of monitoring for their overall survival. The miRNA plasma expression was analyzed by Bio-Rad CFX 96 Manager software to determine the cycle of quantification, followed by the calculation of expression levels using Livak’s methods. Data were analyzed using STATA 11.0, with a significant value of p<0.05. The miRNAs expression of HCC subjects were lower than that healthy control subjects in miRNA-29c (down-regulation 1.83-fold), higher than that healthy control subjects in miRNA 21 and miRNA-155 (up-regulation, 1.74-fold; 1.55-fold) respectively. NLR, CRP, ChE, and platelet count showed a significant difference in miRNA-29c regulation, though neutrophil count showed a significant difference in miRNA-21 and miRNA-155 regulation (p<0.05). Conclusion: Plasma biomarkers: miRNA-21 and miRNA-155 might be potential biomarkers as onco-miR in HCC subjects, while miRNA-29c might act as a tumor suppressor. Significant evidence was identified with clinical progression based on the regulation of miRNAs, which was consistent with miRNA -29c.
format Online
Article
Text
id pubmed-8843218
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88432182022-02-15 Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients Ratnasari, Neneng Lestari, Puji Renovaldi, Dede Raditya Ningsih, Juwita Qoriansas, Nanda Wardana, Tirta Hakim, Suharno Signa Aini Gumilas, Nur Indrarti, Fahmi Triwikatmani, Catharina Bayupurnama, Putut Setyo Heriyanto, Didik Astuti, Indwiani Mubarika Harjana, Sofia PLoS One Research Article This study evaluated differences in the clinical appearance of patients with hepatocellular carcinoma (HCC) based on plasma level and regulation of microRNAs (miRNA-29c, miRNA-21, and miRNA-155). The observational-analytical study with a cross-sectional design was conducted on 36 HCC patients and 36 healthy controls. The blood samples were collected from 2 Province Hospitals (Dr. Sardjito Hospital and Prof. Dr. Margono Soekarjo Hospital) for HCC and the Blood Bank Donor of the Indonesian Red Cross for 36 healthy controls. These blood samples were treated as follows: plasma isolation, RNA isolation, cDNA synthesis, quantification by qRT-PCR using a sequence-specific forward primer, and normalization of miRNA using housekeeping-stably miRNA-16. There were only 27 HCC patients with complete clinical variables (neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), platelet count, albumin, C-reactive protein (CRP), and cholinesterase (ChE)) that were able to analyses for regulation miRNAs based on its fold change expression miRNA target. All 27 HCC subjects were follow-up until 3-years of monitoring for their overall survival. The miRNA plasma expression was analyzed by Bio-Rad CFX 96 Manager software to determine the cycle of quantification, followed by the calculation of expression levels using Livak’s methods. Data were analyzed using STATA 11.0, with a significant value of p<0.05. The miRNAs expression of HCC subjects were lower than that healthy control subjects in miRNA-29c (down-regulation 1.83-fold), higher than that healthy control subjects in miRNA 21 and miRNA-155 (up-regulation, 1.74-fold; 1.55-fold) respectively. NLR, CRP, ChE, and platelet count showed a significant difference in miRNA-29c regulation, though neutrophil count showed a significant difference in miRNA-21 and miRNA-155 regulation (p<0.05). Conclusion: Plasma biomarkers: miRNA-21 and miRNA-155 might be potential biomarkers as onco-miR in HCC subjects, while miRNA-29c might act as a tumor suppressor. Significant evidence was identified with clinical progression based on the regulation of miRNAs, which was consistent with miRNA -29c. Public Library of Science 2022-02-14 /pmc/articles/PMC8843218/ /pubmed/35157721 http://dx.doi.org/10.1371/journal.pone.0263298 Text en © 2022 Ratnasari et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ratnasari, Neneng
Lestari, Puji
Renovaldi, Dede
Raditya Ningsih, Juwita
Qoriansas, Nanda
Wardana, Tirta
Hakim, Suharno
Signa Aini Gumilas, Nur
Indrarti, Fahmi
Triwikatmani, Catharina
Bayupurnama, Putut
Setyo Heriyanto, Didik
Astuti, Indwiani
Mubarika Harjana, Sofia
Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients
title Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients
title_full Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients
title_fullStr Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients
title_full_unstemmed Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients
title_short Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients
title_sort potential plasma biomarkers: mirna-29c, mirna-21, and mirna-155 in clinical progression of hepatocellular carcinoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843218/
https://www.ncbi.nlm.nih.gov/pubmed/35157721
http://dx.doi.org/10.1371/journal.pone.0263298
work_keys_str_mv AT ratnasarineneng potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT lestaripuji potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT renovaldidede potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT radityaningsihjuwita potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT qoriansasnanda potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT wardanatirta potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT hakimsuharno potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT signaainigumilasnur potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT indrartifahmi potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT triwikatmanicatharina potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT bayupurnamaputut potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT setyoheriyantodidik potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT astutiindwiani potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients
AT mubarikaharjanasofia potentialplasmabiomarkersmirna29cmirna21andmirna155inclinicalprogressionofhepatocellularcarcinomapatients